---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-24-000086"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:44:54.956395+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Praxis reports Q2 2024 net loss $32.7M; cash $433.8M; multiple trial milestones on track

## Summary
- Cash and investments $433.8M ($81.3M at Dec 31, 2023); runway into 2027.
- Net loss $32.7M vs $34.3M YoY; R&D expense $27.3M vs $25.6M.
- Ulixacaltamide Essential3 interim analysis in Q4 2024; NDA submission on track for 2025.
- Relutrigine (PRAX-562) Phase 2 EMBOLD topline results expected Q3 2024.
- PRAX-628 Phase 2/3 POWER1 study to start Q4 2024; RADIANT Phase 2 topline H1 2025.

## SEC filing metadata
- accession: 0001689548-24-000086
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954824000086/0001689548-24-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954824000086/prax-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-24-000086
- JSON: https://secwatch.observer/filing/0001689548-24-000086.json
- Plain text: https://secwatch.observer/filing/0001689548-24-000086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.